| Giamarellos-Bourboulis, Evangelos J |
ACCESS, NCT04724044: Anti-inflammatory Action of Oral Clarithromycin in Community-acquired Pneumonia |
|
|
| Completed | 3 | 278 | Europe | Tablets, 2g of intravenous ceftriaxone or one β-lactam/β-lactamase combination(dose adjusted according to renal clearance) or 400mg of intravenous moxifloxacin, Clarithromycin 500mg | Hellenic Institute for the Study of Sepsis | Community-acquired Pneumonia, Sepsis, Inflammatory Response, Mortality, Biomarkers, SIRS | 04/23 | 04/23 | | |
| Recruiting | 3 | 330 | Europe | Clarithromycin 500mg, A β-lactam/β-lactamase inhibitor or a 3rd generation cephalosporin or a fluoroquinolone, Tablets | Hellenic Institute for the Study of Sepsis | Community-acquired Pneumonia | 11/25 | 01/26 | | |
MODIFY, NCT05909683: Assessing the Procalcitonin-guidance and Molecular-guided Diagnosis for Therapy of Severe Infections (the Trial) |
|
|
| Recruiting | 3 | 190 | Europe | Change of antimicrobials based on BCID2 and Reveal Rapid AST tests. Stop of antimicrobials based on PCT results., Standard of Care | Hellenic Institute for the Study of Sepsis | Sepsis | 07/25 | 07/25 | | |
| Recruiting | 2/3 | 182 | Europe | Placebo, Anakinra 149 MG/ML Prefilled Syringe [Kineret] | Hellenic Institute for the Study of Sepsis | Post-Acute COVID-19 Syndrome, Post-Acute COVID-19, Long COVID | 08/25 | 08/25 | | |
NCT05279352: Safety and Pharmacokinetics of FBR-002 for the Treatment of Patients Hospitalized With COVID-19 in Need of Supplemental Oxygen and at Risk of Severe Outcome |
|
|
| Recruiting | 2a | 30 | Europe | FBR-002, Placebo | Fab'entech | COVID-19 | 06/22 | 07/22 | | |
| Completed | 2 | 44 | Europe | Bezlotoxumab, Standard-of-care treatment according to local guidelines or to the decision of the attending physicians., Normal saline 0.9% or 5% dextrose water, Standard-of-care treatment according to local guidelines or to the decision of the attending physicians | Hellenic Institute for the Study of Sepsis | Clostridioides Difficile Infection, Stool Microbiome, Organ Dysfunction Syndrome, Clostridioides Difficile Infection Recurrence, Mortality | 06/23 | 06/23 | | |
NCT04979052: Safety and Efficacy of Interferon-Gamma 1b in Patients with Candidemia |
|
|
| Recruiting | 2 | 200 | Europe, US | Interferon Gamma-1B, Immukin | Radboud University Medical Center, Horizon 2020 - European Commission | Candidemia | 01/27 | 06/27 | | |
| Completed | 2 | 60 | Europe | Anakinra Prefilled Syringe, Kineret, Placebo, NaCl | Hellenic Institute for the Study of Sepsis | Community-acquired Pneumonia, Hospital-acquired Pneumonia | 06/24 | 06/24 | | |
NCT04063332: Functionality of Endogenous Biological Clock in Sepsis |
|
|
| Recruiting | N/A | 60 | Europe | | University of Athens, Hellenic Sepsis Study Group | Circadian Rhythm Disorders, Sepsis | 06/24 | 06/24 | | |
| Completed | N/A | 1450 | Europe, RoW | | University Medicine Greifswald, European Sepsis Alliance, European Society of Anaesthesiology and Intensive Care, European Society for Emergency Medicine (EUSEM) Research Network, European Society of Clinical Microbiology and Infectious Diseases, ESGBIES Study Group, European Society of Intensive Care Medicine, Sepsisdialog, Germany, European Shock Society, Becton, Dickinson and Company | Sepsis | 04/22 | 10/22 | | |
| Completed | N/A | 153 | Europe | Microbiome analysis | Hellenic Institute for the Study of Sepsis | Clostridioides Difficile Infection | 03/22 | 03/22 | | |
SEPSIS-SHIELD, NCT04094818: TriVerity in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis |
|
|
| Completed | N/A | 1441 | Europe, US | TriVerity, InSep, HostDx Sepsis | Inflammatix | Respiratory Tract Infections, Urinary Tract Infections, Intra-Abdominal Infections, Skin and Soft Tissue Infection, Suspected Meningitis/Encephalitis or Any Other Infection, Sepsis | 08/24 | 09/24 | | |
CRONUS, NCT05897801: Distinguishing Bacterial and Viral Infections by MeMed BV® Test to Limit Gut Colonization by MDRO |
|
|
| Completed | N/A | 230 | Europe | MeMed BV® | Hellenic Institute for the Study of Sepsis | Viral Infection, Bacterial Infections, Multi-antibiotic Resistance, Respiratory Tract Infections | 12/23 | 01/24 | | |
BIOARTE, NCT06141395: NGS-Based Assay of Blood Samples of Sepsis Patients for Rapid Bacterial Identification |
|
|
| Completed | N/A | 100 | Europe | NGS-based assay for bacterial identification | Hellenic Institute for the Study of Sepsis, The BioArte | Pneumonia, Acute Pyelonephritis, Bacteremia, Biliary Tract Infection | 03/24 | 03/24 | | |
HOMI-LUNG CAP, NCT06601998: Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19. |
|
|
| Recruiting | N/A | 650 | Europe | Blood samples and Oropharyngeal swab, Six-minute walk test, Spirometry, ECG, Heart ultrasound and cardiopulmonary exercise stress testing, Completion of questionnaires of symptoms | Hellenic Institute for the Study of Sepsis | Pneumonia, Community-Acquired, COVID-19 Pneumonia, Cardiovascular Diseases | 11/27 | 11/27 | | |
POINT, NCT06608849: The Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated with the Post-acute Phase of the Infection by Covid-19 |
|
|
| Not yet recruiting | N/A | 345 | Europe | Blood samples, Six-minute walk test, Spirometry, HRCT, Heart ultrasound, Completion of questionnaires of symptoms | Hellenic Institute for the Study of Sepsis | Pulmonary Complications, Cardiovascular Complications, Renal Complications, COVID-19 | 11/27 | 11/27 | | |
| Recruiting | N/A | 186 | Europe | LactoLevure, Placebo | University of Bari, Uni-Pharma | Ventilator Associated Pneumonia | 05/25 | 05/25 | | |
| Antoniadou, Anastasia |
MARIO, NCT05178862: A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole |
|
|
| Suspended | 3 | 220 | Europe, Canada, US, RoW | SCY-078, Ibrexafungerp, Fluconazole, Diflucan, Echinocandin, Caspofungin, Micafungin, Anidulafungin | Scynexis, Inc. | Candidiasis, Invasive, Candidemia | 06/24 | 08/24 | | |
| Recruiting | 3 | 820 | Europe, US, RoW | Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo | University of Minnesota, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) | COVID, SARS-CoV2 Infection, Covid19 | 08/26 | 08/26 | | |
| Safarika, Asimina |
| Completed | N/A | 153 | Europe | Microbiome analysis | Hellenic Institute for the Study of Sepsis | Clostridioides Difficile Infection | 03/22 | 03/22 | | |
